- Home
- WINT vs LGHL Comparison
WINT vs LGHL Comparison
Compare WINT & LGHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- LGHL
- Stock Information
- Founded
- WINT 1992
- LGHL 2015
- Country
- WINT United States
- LGHL Singapore
- Employees
- WINT N/A
- LGHL N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- LGHL Investment Bankers/Brokers/Service
- Sector
- WINT Health Care
- LGHL Finance
- Exchange
- WINT Nasdaq
- LGHL Nasdaq
- Market Cap
- WINT 2.2M
- LGHL 1.8M
- IPO Year
- WINT 1995
- LGHL N/A
- Fundamental
- Price
- WINT $0.92
- LGHL $3.01
- Analyst Decision
- WINT Hold
- LGHL
- Analyst Count
- WINT 1
- LGHL 0
- Target Price
- WINT $350.00
- LGHL N/A
- AVG Volume (30 Days)
- WINT 25.7M
- LGHL 555.4K
- Earning Date
- WINT 08-18-2025
- LGHL 08-05-2025
- Dividend Yield
- WINT N/A
- LGHL N/A
- EPS Growth
- WINT N/A
- LGHL N/A
- EPS
- WINT N/A
- LGHL N/A
- Revenue
- WINT N/A
- LGHL N/A
- Revenue This Year
- WINT N/A
- LGHL N/A
- Revenue Next Year
- WINT N/A
- LGHL N/A
- P/E Ratio
- WINT N/A
- LGHL N/A
- Revenue Growth
- WINT N/A
- LGHL N/A
- 52 Week Low
- WINT $0.36
- LGHL $2.13
- 52 Week High
- WINT $737.44
- LGHL $20.86
- Technical
- Relative Strength Index (RSI)
- WINT 54.04
- LGHL 47.38
- Support Level
- WINT $0.91
- LGHL $2.71
- Resistance Level
- WINT $1.20
- LGHL $3.64
- Average True Range (ATR)
- WINT 0.22
- LGHL 0.45
- MACD
- WINT 0.01
- LGHL -0.08
- Stochastic Oscillator
- WINT 23.61
- LGHL 19.87
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About LGHL Lion Group Holding Ltd.
Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.